UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 26, 2007
Pipex Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware (State or other jurisdiction of incorporation) |
01-12584 (Commission File Number) |
13-3808303 Identification Number) |
3985 Research Park Drive
Ann Arbor, MI 48108
(Address of principal executive offices) (Zip Code)
(734) 332-7800
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
|
|_| |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|_| |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|_| |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
|
|_| |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
Item 3.01 – Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
The common stock of the Registrant began trading on the American Stock Exchange at the opening of the market on June 26, 2007 under the ticker symbol “PP.”
Item 9.01 Financial Statements and Exhibits.
|
(d) |
Exhibits. |
|
|
Exhibit 99.1 Press Release issued by Pipex Pharmaceuticals, Inc. dated June 26, 2007.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PIPEX PHARMACEUTICALS, INC.
|
|
Dated: June 26, 2007 |
By: /s/ Steve H. Kanzer Steve H. Kanzer, CEO |